Megasys Biotek

What Megasys Biotek does

Megasys Biotek Pvt Ltd is a Kerala-based pharmaceutical contract manufacturer operating a WHO-GMP certified 40,000 sq.ft facility at Kinfra Industrial Park, Koratty, Thrissur. Founded with commercial production commencing in 2010, the company is a subsidiary of Akesiss Pharma Pvt Ltd and manufactures four core dosage forms: oral solids (tablets including bi-layer, chewable, soluble, delayed/extended release), oral liquids (suspensions and solutions), sterile preparations (eye/ear drops), and nasal sprays (including zero-clogging metered sprays). Production capacities are 240 million tablets, 10 million bottles, 6 million sterile SKUs, and 6 million nasal spray SKUs per annum on a single-shift basis.

The company's technical platform centers on cGMP-compliant manufacturing with modern automation, HVAC-controlled environments, unidirectional material flow, 100% power backup, and a dedicated effluent treatment plant. Supporting the manufacturing core are in-house formulation R&D (established November 2017), QA/QC services (HPLC, stability, microbial analysis), custom packaging, and integrated multi-modal logistics leveraging proximity to Cochin International Airport (17 km), Kochi Seaport (45 km), and national highway/rail access. The facility claims compliance with WHO TRS 968, US-FDA, TGA, MHRA, MCC, and ANVISA standards.

Megasys operates a pure B2B contract manufacturing model, serving pharmaceutical companies across India, Asia, Africa, GCC, and North America. Revenue is generated through manufacturing fees and formulation development contracts on a quote-based, multi-year engagement basis via dedicated business development outreach. Named enterprise customers include Micro Labs (5+ year relationship) and Harvey Labs (relationship since inception). The company does not sell directly to end consumers; rather, it manufactures under contract for branded and generic pharma marketers, including those under the Akesiss Group umbrella.

Name

Megasys Biotek

Legal name

Megasys Biotek Pvt Ltd

Website

https://megasysbiotek.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Megasys Biotek Pvt Ltd is a WHO-GMP certified Indian pharmaceutical contract manufacturer producing oral solids, oral liquids, sterile preparations, and nasal sprays from its Kerala facility for domestic and international pharma companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Chemicals & Allied Products (2800)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical contract manufacturing
• WHO-GMP certified manufacturing
• Oral solid dosage forms
• Sterile preparations manufacturing
• Formulation development services

Headquarters

HQ city

Thrissur

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Provides customized formulations and development services for oral solids, oral liquids, sterile preparations and nasal sprays to pharmaceutical companies. Revenue generated through manufacturing fees and formulation development contracts.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Megasys Biotek is a WHO-GMP certified pharmaceutical contract manufacturer producing oral solids (tablets including bi-layer, chewable, soluble, coated, and various release formulations), oral liquids (suspensions and clear solutions), sterile preparations (eye/ear drops), and nasal sprays from a 40,000 sq.ft facility in Kerala, India. The company offers customized formulation development, quality assurance and control services, packaging, and integrated supply chain logistics to pharmaceutical companies in India, Asia, Africa, GCC, and North America.

Product overview

Megasys Biotek is a WHO-GMP certified pharmaceutical manufacturing company offering contract manufacturing services from its 40,000 sq.ft facility in Kerala, India. The company operates as a single integrated manufacturing platform producing four core product categories: Oral Solids (tablets including conventional, bilayer, delayed/extended release, dispersible, chewable formulations), Oral Liquids (suspensions and clear solutions), Sterile Preparations (eye/ear drops), and Nasal Sprays (drops and metered sprays with zero-clog technology). Supporting these manufacturing capabilities are formulation development services, quality assurance/control services, pharmaceutical packaging, and supply chain logistics. The company serves domestic and international markets including Asia, Africa, GCC and North America.

Differentiator

Problem solved

Functional benefit

Products and services

• Oral Solids (Tablets) WHO-GMP certified manufacturing of oral solid dosage forms including conventional tablets, bi-layer tablets, delayed release, extended release (SR), instant and patterned release (IPR), dispersible, chewable, uncoated, film coated and enteric coated tablets, with a capacity of 240 million tablets per annum on single shift basis.
• Oral Liquids Manufacturing of oral liquid formulations including suspensions and clear solutions, with a production capacity of 10 million bottles per annum.
• Sterile Preparations (Eye/Ear Drops) Manufacturing of sterile eye and ear drop preparations, with a production capacity of 6 million SKU per annum.
• Nasal Sprays Manufacturing of nasal spray preparations including drops and metered sprays with zero-clogging technology, with a production capacity of 6 million SKU per annum.
• Contract Manufacturing Services Customized formulation and development services for oral solids, oral liquids, sterile preparations, and nasal sprays for pharmaceutical companies in India, Asia, Africa, GCC, and North America.
• Formulation Development Services In-house R&D services focused on developing new drug formulations, improving existing products and drug delivery systems, and expanding product applications, including clinical and bio-equivalence studies for regulatory approvals.
• Therapeutic Category Products Portfolio Comprehensive product portfolio across therapeutic categories including anti-allergic, antibiotics, anti-depressant, anti-diabetic, anti-inflammatory/analgesic, anti-ulcerants, cardiac disease management, vitamins/minerals, and others.

Quantifiable outcome

• Oral Solids capacity of 240 million tablets per Annum
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Akesiss Pharma Pvt LtdcoreStrategic or Co-development PartnerParent company relationship. Megasys Biotek is a subsidiary of Akesiss Pharma Pvt Ltd. Akesiss Group started with humble marketing operations in southern states and has grown into a major pharma player. Akesiss operates sales and marketing divisions (Zalvo-Gynecology, Glyvo-Diabetology, Lazo-Orthopaedic, Carvo-Cardiology, MSD-Multi speciality, CCD-Critical Care) while Megasys handles formulation development, pharmaceutical manufacturing, and export operations.

Scale indicators7 records

Recent moves1 record

Expansion highlights4 records

Direct peers

• Neuland Laboratories: Indian API and finished-dose contract manufacturer serving global pharma customers with US-FDA inspected facilities. Closely comparable mid-sized Indian CDMO with similar B2B contract manufacturing model, international regulatory focus, and exposure to generic and specialty pharma clients.
• Suven Pharmaceuticals: Indian CDMO providing contract development and manufacturing services for NCEs, intermediates, and APIs with strong US-FDA compliance. Directly comparable mid-sized Indian pharmaceutical contract manufacturer serving global innovator and generic pharma customers.
• Granules India: Indian pharmaceutical manufacturer specializing in oral solid dosages (tablets, capsules) with significant export focus and multiple regulatory certifications. Direct comparable in dosage form, customer base (global generic pharma), and regulatory positioning to Megasys.
• Akums Drugs & Pharmaceuticals: One of India's largest contract manufacturers of finished dosage forms (oral solids, liquids, sterile, topical) serving domestic and international pharma clients. Direct peer in the Indian CDMO space with similar dosage form capabilities and multi-regulatory positioning.

Broad incumbents

• Divis Laboratories: Large Indian API and intermediates CDMO with multiple manufacturing sites, deep R&D, and US-FDA/EMA compliant facilities. Directly comparable to Megasys as an Indian pharmaceutical contract manufacturer serving global pharma customers, but at substantially larger scale and broader service scope.
• Aurobindo Pharma: One of the largest Indian generic pharmaceutical manufacturers with vertically integrated API and finished dosage manufacturing. Comparable in finished dosage contract manufacturing capabilities but operates at vastly larger scale with branded and generic product portfolios.
• Jubilant Pharmova: Indian pharmaceutical company with contract manufacturing operations, dosage form development, and regulatory services across multiple geographies. Comparable as a contract manufacturing and formulation development services provider, though with broader service portfolio.
• Piramal Pharma Solutions: Global CDMO offering sterile injectables, oral solids, and development services across multiple continents. Comparable as a contract manufacturer of finished dosage forms for pharmaceutical clients, but with much greater geographic and technological breadth than Megasys.

Emerging players

• Syngene International: Indian CRO/CDMO providing drug discovery, development, and manufacturing services to global pharma clients. Comparable in serving pharmaceutical customers with development and manufacturing services, but with stronger emphasis on discovery and biologics rather than generic oral solids.

Others

• Ipca Laboratories:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Megasys Biotek